Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Eli Lilly and Co (LLY) is trading at $1,186.39, up 3.08% on the day. Its market value of $1.12T makes it the 12th largest of the 300 companies we follow.
Over the past 52 weeks it has traded between $711.59 and $1,292.65, so it sits 8.2% below the top of that range. Holders are ahead 60.9% over twelve months, and up 6.3% across the last three months.
On the chart it holds above both the 50-day ($1,176.17) and 200-day ($1,065.73) moving averages; RSI is 51, and the last 30 sessions moved at roughly 26% annualized volatility.
Revenue for the quarter ended Jun 2026 was $22.97B, up 47.7% from a year earlier, with $7.10B of net profit (a 33.5% margin).
The stock changes hands at 39.8 times trailing earnings, 41% below its five-year average of 67.5. The median for its industry group is 20.4.
21 analysts follow the stock and the average call is "buy". The mean target, $1,372.58, sits 15.7% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Eli Lilly develops diabetes, obesity, cancer and immunology drugs, including Mounjaro, Zepbound and Verzenio.
What tends to move it. Sales of its GLP-1 obesity and diabetes drugs, supply capacity and competition from Novo Nordisk drive the stock.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +3.0% | Bullish |
| Price vs 50-day average | +0.9% | Bullish |
| Price vs 200-day average | +11.3% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 51.1 | Bullish |
| MACD (12,26,9) | -7.03 | Bullish |
| Bollinger band position | 93% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 5th percentile, 5-year average 67.5x
#2293 of 2977 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 12th percentile, 5-year average 43.0x
#5176 of 5304 stocks by PB (1 = cheapest)
Below its usual level · 36th percentile, 5-year average 14.9x
#4520 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: +$97.57M (11 inflow days, 9 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 15.0% a year.
$1,186.39 is the latest print for LLY, a move of +3.08% against yesterday's close of $1,150.99. Today's low and high so far: $1,151.01 and $1,197.75.
Equity value comes to $1.12T at the current price. By that measure it is number 12 of the 300 names in our coverage.
Buyers pay 39.8 times the last twelve months of profit (EPS $22.95). Averaged over five years the multiple has been 67.5, and today's level ranks in the 5th percentile of its own history.
The year's floor is $711.59 and the ceiling $1,292.65. Shares are 8.2% away from that ceiling.
It does. Payouts over the past twelve months work out to a 0.54% yield; the latest ex-dividend date was August 14, 2026.
Of 21 analysts, 86% say buy, 10% hold and 5% sell. Price targets average $1,372.58, with the most cautious at $940.00 and the most optimistic at $1,600.00.
Eli Lilly develops diabetes, obesity, cancer and immunology drugs, including Mounjaro, Zepbound and Verzenio.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.